ArticleThe Lancet. Infectious diseases2020
Estimates of the severity of coronavirus disease 2019: a model-based analysis.
Article in The Lancet. Infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 8 registered trials, which are not on this map. Cited by 1,869 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Repurposing of Chlorpromazine in Covid-19 Treatment
Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection
Safety and Efficacy of Post-exposure Prophylaxis With Hydroxychloroquine (HCQ) for the Prevention of COVID-19 in High-risk Older Individuals in Long-term and Specialized Care: A Double-blind Randomized Control Trial
Early Thromboprophylaxis in COVID-19 (ETHIC Trial): an Open Label, Randomized Phase IIIb Trial of Community-based (LMWH) Versus Standard of Care (no Enoxaparin) in COVID-19 Positive Patients
Prospective Determination of COVID-19 Infection Rate in Patients With Solid Tumors and Healthcare Workers of the Chemotherapy and Radiotherapy Unit at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador.
Evaluation of the Daily Intake of 0.5 L of Water Saturated With Molecular Hydrogen for 21 Days in COVID-19 Patients Treated in Ambulatory Care. Double-blind, Randomized, Comparative Study
Assessment of Efficacy and Safety of Anodal Transcranial Direct Current Stimulation (TDCS) in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemics
Pilot Phase II Randomized, Placebo-Controlled Clinical Trial for the Prevention and Progression of SARS-CoV-2 Infection of Subjects and Patients Using a Supplement Treatment With Carnipure Tartrate ( LCLT)
Who cites it
1,869 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Systematic Review and Meta-Analysis of Emerging Viral Zoonotic Diseases, 2016-2026.Transboundary and emerging diseases · 2026Pooled it
- Hemoadsorption in acute respiratory distress syndrome patients requiring venovenous extracorporeal membrane oxygenation: a systematic review.Respiratory research · 2024Pooled it
- Assessment of the available therapeutic approaches for severe COVID-19: a meta-analysis of randomized controlled trials.Scientific reports · 2023Pooled it
- The Impact of COVID-19 on the Prevalence, Mortality, and Associated Risk Factors for Mortality in Patients with Hip Fractures: A Meta-Analysis.Journal of the American Medical Directors Association · 2023Pooled it
- Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes.The Journal of infection · 2024Trial
- Trial
- Significant but small: the modest impact of population ageing on reported COVID-19 case rates worldwide.Future science OA · 2026Article
- Agreement between seroprevalence- and model-based estimates of COVID-19 burden.Global health action · 2026Article
- A late-stage multi-dimensional intervention rescues lethal viral pneumonia in an aged hamster model.Molecular biomedicine · 2026Article
- Pathogens and clinical characteristics of type 2 diabetes mellitus in patients with community-acquired pneumonia via bronchoalveolar lavage fluid (BALF) metagenomic next-generation sequencing: a comparative observational study.Journal of thoracic disease · 2026Article
- Dynamic Cytokine and Coagulation Profiling in Patients With Severe COVID‑19 Evaluated for Pulmonary Embolism: A Prospective Cohort Study.Medical science monitor : international medical journal of experimental and clinical research · 2026Observational
- Using forensic autopsy data to estimate the age-specific infection fatality risk of COVID-19.Epidemiology and infection · 2026Article
- Article
- A Bayesian estimator of the real-time case fatality rate in emerging pandemic to inform public health policy-making.BMC infectious diseases · 2026Article
- Implementing a multi-centric cohort study during the SARS-CoV-2 pandemic in a resource-constrained setting: challenges, adaptive solutions, and lessons from Brazil.Archives of public health = Archives belges de sante publique · 2026Article
- COVID-19, infection fatality rate (IFR) implied by the serology, antibody, testing in New York City.Infectious Disease Modelling · 2026Article
- Modeling and Simulation of the Role of Mass Testing in Controlling COVID-19.Bulletin of mathematical biology · 2026Article
- Musculoskeletal Pain Among Community-Dwelling Older Adults During the COVID-19 Pandemic: A Longitudinal Telesurvey.Physiotherapy Canada. Physiotherapie Canada · 2026Article
- Effectiveness and Safety of COVID-19 Vaccination in Patients With Heart Failure: A Nationwide Retrospective Cohort Study.Korean circulation journal · 2026Article
- On urban maladaptation in times of epidemics.Scientific reports · 2026Article
1,809 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
- Erratum issued
Authors and funding
33 authors.
Funding
Abstract
backgroundIn the face of rapidly changing data, a range of case fatality ratio estimates for coronavirus disease 2019 (COVID-19) have been produced that differ substantially in magnitude. We aimed to provide robust estimates, accounting for censoring and ascertainment biases.
methodsWe collected individual-case data for patients who died from COVID-19 in Hubei, mainland China (reported by national and provincial health commissions to Feb 8, 2020), and for cases outside of mainland China (from government or ministry of health websites and media reports for 37 countries, as well as Hong Kong and Macau, until Feb 25, 2020). These individual-case data were used to estimate the time between onset of symptoms and outcome (death or discharge from hospital). We next obtained age-stratified estimates of the case fatality ratio by relating the aggregate distribution of cases to the observed cumulative deaths in China, assuming a constant attack rate by age and adjusting for demography and age-based and location-based under-ascertainment. We also estimated the case fatality ratio from individual line-list data on 1334 cases identified outside of mainland China. Using data on the prevalence of PCR-confirmed cases in international residents repatriated from China, we obtained age-stratified estimates of the infection fatality ratio. Furthermore, data on age-stratified severity in a subset of 3665 cases from China were used to estimate the proportion of infected individuals who are likely to require hospitalisation.
findingsUsing data on 24 deaths that occurred in mainland China and 165 recoveries outside of China, we estimated the mean duration from onset of symptoms to death to be 17·8 days (95% credible interval [CrI] 16·9-19·2) and to hospital discharge to be 24·7 days (22·9-28·1). In all laboratory confirmed and clinically diagnosed cases from mainland China (n=70 117), we estimated a crude case fatality ratio (adjusted for censoring) of 3·67% (95% CrI 3·56-3·80). However, after further adjusting for demography and under-ascertainment, we obtained a best estimate of the case fatality ratio in China of 1·38% (1·23-1·53), with substantially higher ratios in older age groups (0·32% [0·27-0·38] in those aged <60 years vs 6·4% [5·7-7·2] in those aged ≥60 years), up to 13·4% (11·2-15·9) in those aged 80 years or older. Estimates of case fatality ratio from international cases stratified by age were consistent with those from China (parametric estimate 1·4% [0·4-3·5] in those aged <60 years [n=360] and 4·5% [1·8-11·1] in those aged ≥60 years [n=151]). Our estimated overall infection fatality ratio for China was 0·66% (0·39-1·33), with an increasing profile with age. Similarly, estimates of the proportion of infected individuals likely to be hospitalised increased with age up to a maximum of 18·4% (11·0-37·6) in those aged 80 years or older.
interpretationThese early estimates give an indication of the fatality ratio across the spectrum of COVID-19 disease and show a strong age gradient in risk of death.
fundingUK Medical Research Council.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.